Champions Oncology
NASDAQ: CSBRHackensack, US · Founded 2007 · Delaware corporation · 184 employees on LinkedIn · 3 known investors
Find your way into Champions Oncology
1,244 people in our graph share verified history with the Champions Oncology team — schools, employers, funds. One of them is your warm intro.
Stephane Kurganunlockedknows Rob Brainin · together at McKinsey & Company (overlapped)
knows the team · via McKinsey & Company
×3knows the team · via Harvard Medical School
×4knows the team · via University of Pennsylvania
knows the team · via Yale School of Medicine
knows the team · via Code Ocean
Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance. It serves pharma and biotech teams developing KRAS-directed cancer therapies for NSCLC, pancreatic (PDAC), and colorectal cancers, providing benchmarking, biomarker, and combination-strategy evidence.
Founders & leadership
Champions Oncology was founded in 2007 by Ronnie Morris and Ronnie Morris, M.D..
RM
Ronnie MorrisinCo-founder · President
RM
Ronnie Morris, M.D.inCo-founder · President
JM
James McGorryExecutive
DM
JA
Joel AckermaninChief Executive Officer2010–2017
RB
Rob BrainininChief Executive OfficerHe previously served as Chief Business Officer at Veracyte and CEO at Genuity Science, where he focused on molecular data and data science applications in drug discovery. Earlier, he held executive roles at Illumina leading Life Sciences & Applied Genomics, and at Life Technologies/Thermo Fisher across multiple business units including cell culture, genomics, and drug safety testing. He also worked as a consultant at McKinsey & Co.
MM
Maria ManciniinChief Operating OfficerMaria Mancini is Chief Operating Officer of Champions Oncology, a preclinical platform company specializing in KRAS-focused drug development for cancer. She brings experience in oncology biotechnology and preclinical cancer research.
MZ
Marianna ZipetoinEVP, Growth, Strategy & EnablementMarianna Zipeto is an oncology services executive with over a decade of experience in commercial leadership, strategic partnerships, and business growth. She leads growth strategy, sales enablement, and partnership initiatives at Champions Oncology.
TF
Tammer FaridinGeneral Manager, Data BusinessTammer Farid is General Manager of the Data Business at Champions Oncology. He previously worked as a management consultant advising health care and biopharmaceutical companies on strategy and go-to-market planning, and holds a B.A. in chemistry and Ph.D. in biophysics and biochemistry.
PB
Philip BreitfeldinChief Strategy & Innovation Officer
Board
DS
AE
Arthur Epker, IIIBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$16M disclosed across 3 rounds · 2012–2015
▶$14MraisedMar 2015 · 11 investors · BiotechnologyRule 506(b)
▶$14MraisedMar 2015 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James McGorryExecutive Officer
- David MillerExecutive Officer
- Daniel MendelsonDirector
- Joel AckermanExecutive Officer, Director
- Abba David PoliakoffDirector
- David SidranskyDirector
- Arthur Epker, IIIDirector
- Scott TobinDirector
- Ronnie MorrisExecutive Officer, Director
- Offering amount
- $14M
- Amount sold
- $14M
- Minimum investment
- $1
- Sales commissions
- $640.5K
- Placement agents
- MTS Securities, LLC
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedDec 2014 · 2 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joel AckermanExecutive Officer, Director
- Scott TobinDirector
- Abba David PoliakoffDirector
- Arthur Epker, IIIDirector
- David SidrankskyDirector
- David MillerExecutive Officer
- Ronnie MorrisDirector
- Daniel MendelsonDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $1M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.5KraisedFeb 2012 · 1 investors · BiotechnologyRule 506(b)
▶$8.5KraisedFeb 2012 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joel AckermanExecutive Officer, Director
- David Sidransky, M.D.Director
- Scott TobinDirector
- Ronnie Morris, M.D.Executive Officer, Director
- Abba D. PoliakoffDirector
- James M. MartellDirector
- Ana I. StancicDirector
- Offering amount
- $8.5K
- Amount sold
- $8.5K
- Minimum investment
- $8.5K
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$24.1Mvaluation at IPOJun 2016 · $2.25/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 3
by search overlap
Labcorp241 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Abcam152 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
Crownbio138 shared keywordsCrown Bioscience is a contract research organization based in California providing discovery, preclinical, and translational platforms and services for oncology and immuno-oncology drug development. The company serves pharmaceutical and biotech companies seeking to advance and de-risk their drug development programs.
Companies competing with Champions Oncology for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Champions Oncology do?
- Champions Oncology offers a KRAS-focused preclinical platform built on patient-derived xenograft (PDX) models screened with the pan-RAS(ON) inhibitor daraxonrasib, combining in vivo pharmacology with multi-omic characterization to study drug response and resistance. It serves pharma and biotech teams developing KRAS-directed cancer therapies for NSCLC, pancreatic (PDAC), and colorectal cancers, providing benchmarking, biomarker, and combination-strategy evidence.
- Who founded Champions Oncology?
- Champions Oncology was founded by Ronnie Morris, Ronnie Morris, M.D. in 2007.
- Who are Champions Oncology's investors?
- Champions Oncology's investors include Battery Ventures, New Enterprise Associates (NEA), Israel Biotech Fund.
- How much funding has Champions Oncology raised?
- Champions Oncology has disclosed $16M raised across 3 rounds.
- Where is Champions Oncology headquartered?
- Champions Oncology is headquartered in Hackensack, US.